2015 Fiscal Year Final Research Report
Genome- and gene expression-based drug discovery for pediatric Philadelphia chromosome positive leukemia
| Project/Area Number |
25461608
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIMA HARUKO 慶應義塾大学, 医学部, 助教 (80424167)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KIYOKAWA NOBUTAKA 独立行政法人国立成育医療研究センター, 小児血液・腫瘍研究部, 部長 (60195401)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 慢性骨髄性白血病 / フィラデルフィア染色体陽性急性リンパ性白血病 / IKZF1遺伝子 / ゲノム解析 |
|---|
| Outline of Final Research Achievements |
Deletion of IKZF1 gene was reported to be found in 80% of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), which is known to be refractory leukemia. We examined the association between IKZF1 deletion and prognosis of 40 Ph+ALL patients, who was registered into the JPLSG Ph+ALL04 study. As a result, 4-year event-free survival was 89% in patients without IKZF1 deletion and 42% in patients with IKZF1 deletion. Patients with IKZF1 deletion had a significantly higher rate of relapse than those without IKZF1 deletion. These results suggest that the reason why Ph+ALL is refractory is not the appearance of Ph-chromosome but deletion of IKZF1.
|
| Free Research Field |
小児血液・腫瘍
|
